T1	Participants 194 232	patients with atrial fibrillation (AF)
T2	Participants 812 892	Patients who were VKA-naive and experienced are included in balanced proportions
T3	Participants 757 811	Recruitment concluded with a total of 18,113 patients.
T4	Participants 595 755	RE-LY is a phase 3, prospective, randomized, open-label multinational (44 countries) trial of patients with nonvalvular AF and at least 1 risk factor for stroke
